ERBB2 and cholangiocarcinoma: Together, these suggest the potential application of specific HER2 targeting immunotherapy for HER2-altered CCA clusters with favorable clinical outcomes and emphasize further developing alternative treatment strategies for CCA patients [118,179,182].